Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141336 · ClinicalTrials.gov registry record · Phase 3
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
A Phase 3 study of Seizure Disorder, Partial, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
- 20
- Study locations
NCT00141336 is a Phase 3 study of Seizure Disorder, Partial that has completed, run by Pfizer. The registered enrollment target is 750 participants. The trial reports 20 study locations across 3 states.
The verdict
NCT00141336, a Phase 3 study of Seizure Disorder, Partial, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the long-term safety and tolerability of pregabalin in patients with partial seizures.
Conditions Studied
Interventions
- DRUG Pregabalin
Study Locations (20)
California
- Pfizer Investigational Site - Bakersfield
- Pfizer Investigational Site - Berkeley
- Pfizer Investigational Site - Concord
- Pfizer Investigational Site - Covina
- Pfizer Investigational Site - El Cajon
- Pfizer Investigational Site - Encino
- Pfizer Investigational Site - La Mesa
- Pfizer Investigational Site - Marina Del Ray
- Pfizer Investigational Site - Martinez
- Pfizer Investigational Site - Northridge
- Pfizer Investigational Site - Pinole
- Pfizer Investigational Site - Redondo Beach
- Pfizer Investigational Site - Sacramento
- Pfizer Investigational Site - Sacramento
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - Santa Monica
- Pfizer Investigational Site - Walnut Creek
Arizona
- Pfizer Investigational Site - Phoenix
- Pfizer Investigational Site - Tucson
Colorado
- Pfizer Investigational Site - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 1999-11 |
| Est. Completion | 2005-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00141336
The ClinicalTrials.gov registry entry for NCT00141336 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seizure Disorder, Partial appearing as the primary indexed condition, and to 1 intervention - of which Pregabalin is the first listed.
NCT00141336 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT00141336 about?
NCT00141336 is a clinical study titled "To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.". To evaluate the long-term safety and tolerability of pregabalin in patients with partial seizures.
What is the current status of trial NCT00141336?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 1999-11. Estimated completion is 2005-07.
What conditions does trial NCT00141336 study?
This clinical trial studies the following conditions: Seizure Disorder, Partial.
What interventions are being tested in trial NCT00141336?
The interventions under investigation include: Pregabalin (DRUG).
Who is sponsoring clinical trial NCT00141336?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00141336 being conducted?
This trial has 20 study locations across Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.